Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medigen BiotechnologyROCO:3176 +2.31%58 Gross Margin % is 56.72% as of Dec. 2025, which is 27% above its 10-year median of 44.60. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$49.63 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 732 Biotechnology companies, Medigen Biotechnology ranks worse than 53.69% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medigen Biotechnology had a gross margin of 56.72% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medigen Biotechnology Gross Margin % Related Terms
Medigen Biotechnology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Medigen Biotechnology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3176 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Medigen Biotechnology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medigen Biotechnology (ROCO:3176) has a Gross Margin % of 56.72% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Medigen Biotechnology and its competitors. This is 27% above median its historical median of 44.60. Over the past decade, Medigen Biotechnology's Gross Margin % has ranged from 8.28 to 65.05. According to the industry distribution chart, Medigen Biotechnology ranks #393 out of 732 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Medigen Biotechnology's Gross Margin % too high?
Medigen Biotechnology's current Gross Margin % of 56.72% is 27% above median its 10-year median of 44.60. Over the past 10 years, this metric has ranged from a low of 8.28 to a high of 65.05. The Biotechnology industry median Gross Margin % is 60.91. Medigen Biotechnology's value of 56.72% is 6.9% below this industry median. Based on the distribution chart, Medigen Biotechnology ranks #393 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Biotechnology ranks #393 out of 732 companies for Gross Margin %. This places Medigen Biotechnology in the lower half of its industry. The industry median Gross Margin % is 60.91. Medigen Biotechnology's value of 56.72% is 6.9% below this benchmark. Historically, Medigen Biotechnology's own Gross Margin % has ranged from 8.28 to 65.05 over the past decade. While the company's 10-year median is 44.60 vs. the industry median of 60.91, Medigen Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Biotechnology's current Gross Margin % of 56.72% is 6.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medigen Biotechnology and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Biotechnology's current Gross Margin % is 56.72%, which is 27% above median its own 10-year median of 44.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$49.63, compared to a current price of NT$35.40 — trading 28.7% below its estimated fair value. The current Gross Margin % is 56.72%, which is 27% above median its 10-year median of 44.60 and 6.9% below the Biotechnology industry median of 60.91. Medigen Biotechnology's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Gross Margin % is 56.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued.
The current stock price of NT$35.40 is trading 28.7% below its estimated GF Value™ of NT$49.63.
GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3176:
Gross Margin %: 56.72% (27% above median its 10-year median of 44.60)
GF Value™: NT$49.63 vs. price of NT$35.40 (28.7% below fair value)
Industry Position: 6.9% below the Biotechnology median (#393 of 732)
No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score
Get the complete analysis for ROCO:3176
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3176 has been successfully added to your 
